Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)

Critical Care Medicine

Volumn 48, Issue 6, 2020, Pages E440-E469

  Alhazzani, Waleed ^a   Møller, Morten Hylander ^b,c   Arabi, Yaseen M ^d   Loeb, Mark ^a   Gong, Michelle Ng ^e   Fan, Eddy ^f   Oczkowski, Simon ^a   Levy, Mitchell M ^g,h   Derde, Lennie ⁱ   Dzierba, Amy ^j   Du, Bin ^k   Aboodi, Michael ^e   Wunsch, Hannah ^l,m   Cecconi, Maurizio ^n,o   Koh, Younsuck ^p   Chertow, Daniel S ^q   Maitland, Kathryn ^r   Alshamsi, Fayez ^s   Belley Cote, Emilie ^a,t   Greco, Massimiliano ^n,o   Laundy, Matthew ^u   Morgan, Jill S ^v   Kesecioglu, Jozef ⁱ   McGeer, Allison ^f   Mermel, Leonard ^g   Mammen, Manoj J ^w   Alexander, Paul E ^a,x   Arrington, Amy ^y   Centofanti, John E ^a   Citerio, Giuseppe ^z,aa   Baw, Bandar ^a,ab   Memish, Ziad A ^ac   Hammond, Naomi ^ad,ae   Hayden, Frederick G ^af   Evans, Laura ^ag   Rhodes, Andrew ^u   more..

^a MCMASTER UNIVERSITY   (Canada)

^b Rigshospitalet   (Denmark)

^c Scandinavian Society of Anaesthesiology and Intensive Care Medicine   (Denmark)

^d KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g BROWN UNIVERSITY   (United States)

^h RHODE ISLAND HOSPITAL   (United States)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j NewYork Presbyterian Hospital   (United States)

^k PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^l SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^m UNIVERSITY OF TORONTO   (Canada)

ⁿ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^o HUMANITAS UNIVERSITY   (Italy)

^p University of Ulsan College of Medicine   (South Korea)

^q NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^r IMPERIAL COLLEGE LONDON   (United Kingdom)

^s UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^t MCMASTER UNIVERSITY   (Canada)

^u ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^v EMORY UNIVERSITY HOSPITAL   (United States)

^w UNIVERSITY AT BUFFALO   (United States)

^x GUIDE Research Methods Group   (Canada)

^y BAYLOR COLLEGE OF MEDICINE   (United States)

^z UNIVERSITY OF MILANO BICOCCA   (Italy)

^aa SAN GERARDO HOSPITAL   (Italy)

^ab KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^ac MINISTRY OF HEALTH   (Saudi Arabia)

^ad GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^ae ROYAL NORTH SHORE HOSPITAL   (Australia)

^af UNIVERSITY OF VIRGINIA   (United States)

^ag School of Medicine   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL VENTILATION; BETACORONAVIRUS; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; CRITICAL ILLNESS; DIAGNOSTIC PROCEDURE; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; ORGANIZATION AND MANAGEMENT; PANDEMIC; PRACTICE GUIDELINE; PROCEDURES; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SHOCK; VIRUS PNEUMONIA;

BETACORONAVIRUS; CORONAVIRUS INFECTIONS; CRITICAL ILLNESS; DIAGNOSTIC TECHNIQUES AND PROCEDURES; HUMANS; INFECTION CONTROL; INTENSIVE CARE UNITS; PANDEMICS; PNEUMONIA, VIRAL; PRACTICE GUIDELINES AS TOPIC; RESPIRATION, ARTIFICIAL; SHOCK;

EID: 85085215137     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000004363     Document Type: Article

References (223)

1. Guan WJ, Ni ZY, Hu Y,. China Medical Treatment Expert Group for COVID-19: Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020 Feb 28. [online ahead of print]
2. European Centre for Disease Prevention and Control: Situation update worldwide. 2020. Available at: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases. Accessed March 4, 2020
3. Alhazzani W, Lewis K, Jaeschke R,. Conflicts of interest disclosure forms and management in critical care clinical practice guidelines. Intensive Care Med 2018; 44: 1691-1698
4. Vandvik PO, Alhazzani W, Møller MH,. Understanding conflicts of interest. Intensive Care Med 2018; 44: 1738-1740
5. Guyatt GH, Oxman AD, Kunz R,. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 2011; 64: 395-400
6. Akl EA, Johnston BC, Alonso-Coello P,. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLoS One 2013; 8: e57132
7. Guyatt GH, Oxman AD, Vist GE, GRADE Working Group: GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926
8. Balshem H, Helfand M, Schunemann HJ,. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64: 401-406
9. Andrews J, Guyatt G, Oxman AD,. GRADE guidelines: 14. Going from evidence to recommendations: The significance and presentation of recommendations. J Clin Epidemiol 2013; 66: 719-725
10. Guyatt GH, Oxman AD, Santesso N,. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol 2013; 66: 158-172
11. Schunemann HJ, Wiercioch W, Brozek J,. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol 2017; 81: 101-110
12. Wu Z, McGoogan JM,. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020 Feb 24. [online ahead of print]
13. Livingston E, Bucher K,. Coronavirus disease 2019 (COVID-19) in Italy. JAMA 2020 Mar 17. [online ahead of print].
14. Milton DK, Fabian MP, Cowling BJ,. Influenza virus aerosols in human exhaled breath: Particle size, culturability, and effect of surgical masks. PLoS Pathog 2013; 9: e1003205
15. Twu SJ, Chen TJ, Chen CJ,. Control measures for severe acute respiratory syndrome (SARS) in Taiwan. Emerg Infect Dis 2003; 9: 718-720
16. World Health Organization: Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. 2020. Available at: https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf?sfvrsn=bc7da517_10&download=true. Accessed March 14, 2020
17. Cabrini L, Landoni G, Zangrillo A,. Minimise nosocomial spread of 2019-nCoV when treating acute respiratory failure. Lancet 2020; 395: 685
18. Yam LYC, Chen RC, Zhong NS,. SARS: Ventilatory and intensive care. Respirology 2003; (8 Suppl): S31-S35
19. Qian H, Li Y, Sun H,. Particle removal efficiency of the portable HEPA air cleaner in a simulated hospital ward. Building Simulation 2010; 3: 215-224
20. Smith JD, MacDougall CC,. Effectiveness of N95 respirators versus surgical masks in protecting health care workers from acute respiratory infection: A systematic review and meta-analysis. CMAJ 2016; 188: 567-574
21. Radonovich LJ Jr., Simberkoff MS, Bessesen MT,. N95 respirators vs medical masks for preventing influenza among health care personnel: A randomized clinical trial. JAMA 2019; 322: 824-833
22. Loeb M, Dafoe N, Mahony J,. Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial. JAMA 2009; 302: 1865-1871
23. MacIntyre CR, Wang Q, Cauchemez S,. A cluster randomized clinical trial comparing fit-tested and non-fit-tested N95 respirators to medical masks to prevent respiratory virus infection in health care workers. Influenza Other Respir Viruses 2011; 5: 170-179
24. MacIntyre CR, Wang Q, Rahman B,. Efficacy of face masks and respirators in preventing upper respiratory tract bacterial colonization and co-infection in hospital healthcare workers. Prev Med 2014; 62: 1-7
25. MacIntyre CR, Wang Q, Seale H,. A randomized clinical trial of three options for N95 respirators and medical masks in health workers. Am J Respir Crit Care Med 2013; 187: 960-966
26. Long Y, Hu T, Liu L,. Effectiveness of N95 respirators versus surgical masks against influenza: A systematic review and meta-analysis. J Evid Based Med 2020 Mar 13. [online ahead of print]
27. Tuite AR, Fisman DN,. Reporting, epidemic growth, and reproduction numbers for the 2019 novel coronavirus (2019-nCoV) epidemic. Ann Intern Med 2020 Feb 5. [online ahead of print]
28. Biggerstaff M, Cauchemez S, Reed C,. Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: A systematic review of the literature. BMC Infect Dis 2014; 14: 480
29. Tran K, Cimon K, Severn M,. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PLoS One 2012; 7: e35797
30. Lewis SR, Butler AR, Parker J,. Videolaryngoscopy versus direct laryngoscopy for adult patients requiring tracheal intubation: A Cochrane Systematic Review. Br J Anaesth 2017; 119: 369-383
31. Lewis SR, Butler AR, Parker J,. Videolaryngoscopy versus direct laryngoscopy for adult patients requiring tracheal intubation. Cochrane Database Syst Rev 2016; 11: CD011136
32. Russell TM, Hormis A, Rotherham NHS Foundation Trust: Should the Glidescope video laryngoscope be used first line for all oral intubations or only in those with a difficult airway? A review of current literature. J Perioper Pract 2018; 28: 322-333
33. Centers for Disease Control and Prevention: Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons Under Investigation (PUIs) for Coronavirus Disease 2019 (COVID-19). Available at: https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html. Accessed February 14, 2020
34. Linton NM, Kobayashi T, Yang Y,. Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: A statistical analysis of publicly available case data. J Clin Med 2020; 9: 538
35. Corman VM, Landt O, Kaiser M,. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020; 25: 2000045
36. Chu DKW, Pan Y, Cheng SMS,. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin Chem 2020; 66: 549-555
37. Xie C, Jiang L, Huang G,. Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests. Int J Infect Dis 2020; 93: 264-267
38. Yam WC, Chan KH, Poon LL,. Evaluation of reverse transcription-PCR assays for rapid diagnosis of severe acute respiratory syndrome associated with a novel coronavirus. J Clin Microbiol 2003; 41: 4521-4524
39. Ai T, Yang Z, Hou H,. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: A report of 1014 Cases. Radiology 2020 Feb 26. [online ahead of print]
40. Wu X, Cai Y, Huang X,. Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia, China. Emerg Infect Dis 2020 Mar 11. [online ahead of print]
41. Chan PK, To WK, Ng KC,. Laboratory diagnosis of SARS. Emerg Infect Dis 2004; 10: 825-831
42. Yang X, Yu Y, Xu J,. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med 2020 Feb 24. [online ahead of print]
43. Wang D, Hu B, Hu C,. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061-1069
44. Huang C, Wang Y, Li X,. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506
45. Zhou F, Yu T, Du R,. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020; 395: 1054-1062
46. Ruan Q, Yang K, Wang W,. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020 Mar 3. [online ahead of print]
47. Bednarczyk JM, Fridfinnson JA, Kumar A,. Incorporating dynamic assessment of fluid responsiveness into goal-directed therapy: A systematic review and meta-analysis. Crit Care Med 2017; 45: 1538-1545
48. Bentzer P, Griesdale DE, Boyd J,. Will this hemodynamically unstable patient respond to a bolus of intravenous fluids? JAMA 2016; 316: 1298-1309
49. Pan J, Peng M, Liao C,. Relative efficacy and safety of early lactate clearance-guided therapy resuscitation in patients with sepsis: A meta-analysis. Medicine (Baltimore) 2019; 98: e14453
50. Hernandez G, Ospina-Tascon GA, Damiani LP,. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: The ANDROMEDA-SHOCK randomized clinical trial. JAMA 2019; 321: 654-664
51. Meyhoff TS, Moller MH, Hjortrup PB,. Lower versus higher fluid volumes during initial management of sepsis: A systematic review with meta-analysis and trial sequential analysis. Chest 2020 Jan 23. [online ahead of print]
52. Silversides JA, Major E, Ferguson AJ,. Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: A systematic review and meta-analysis. Intensive Care Med 2017; 43: 155-170
53. Maitland K, Kiguli S, Opoka RO,. Mortality after fluid bolus in African children with severe infection. N Engl J Med 2011; 364: 2483-2495
54. Lewis SR, Pritchard MW, Evans DJ,. Colloids versus crystalloids for fluid resuscitation in critically ill people. Cochrane Database Syst Rev 2018; 8: CD000567
55. Antequera Martin AM, Barea Mendoza JA, Muriel A,. Buffered solutions versus 0.9% saline for resuscitation in critically ill adults and children. Cochrane Database Syst Rev 2019; 7: CD012247
56. Moller MH, Claudius C, Junttila E,. Scandinavian SSAI clinical practice guideline on choice of first-line vasopressor for patients with acute circulatory failure. Acta Anaesthesiol Scand 2016; 60: 1347-1366
57. Gamper G, Havel C, Arrich J,. Vasopressors for hypotensive shock. Cochrane Database Syst Rev 2016; 2: CD003709
58. Honarmand K, Um KJ, Belley-Cote EP,. Canadian Critical Care Society clinical practice guideline: The use of vasopressin and vasopressin analogues in critically ill adults with distributive shock. Can J Anaesth 2020; 67: 369-376
59. McIntyre WF, Um KJ, Alhazzani W,. Association of vasopressin plus catecholamine vasopressors vs catecholamines alone with atrial fibrillation in patients with distributive shock: A systematic review and meta-analysis. JAMA 2018; 319: 1889-1900
60. Lamontagne F, Day AG, Meade MO,. Pooled analysis of higher versus lower blood pressure targets for vasopressor therapy septic and vasodilatory shock. Intensive Care Med 2018; 44: 12-21
61. Lamontagne F, Richards-Belle A, Thomas K, 65 Trial Investigators: Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with vasodilatory hypotension: A randomized clinical trial. JAMA 2020; 323: 938-949
62. Moller MH, Granholm A, Junttila E,. Scandinavian SSAI clinical practice guideline on choice of inotropic agent for patients with acute circulatory failure. Acta Anaesthesiol Scand 2018; 62: 420-450
63. Rygard SL, Butler E, Granholm A,. Low-dose corticosteroids for adult patients with septic shock: A systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 2018; 44: 1003-1016
64. Lamontagne F, Rochwerg B, Lytvyn L,. Corticosteroid therapy for sepsis: A clinical practice guideline. BMJ 2018; 362: k3284
65. Chen N, Zhou M, Dong X,. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020; 395: 507-513
66. van den Boom W, Hoy M, Sankaran J,. The search for optimal oxygen saturation targets in critically ill patients: Observational data from large icu databases. Chest 2020; 157: 566-573
67. Chu DK, Kim LH, Young PJ,. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): A systematic review and metaanalysis. Lancet 2018; 391: 1693-1705
68. Siemieniuk RAC, Chu DK, Kim LH,. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. BMJ 2018; 363: k4169
69. Mackle D, R, ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Conservative oxygen therapy during mechanical ventilation in the ICU. N Engl J Med 2020; 382: 989-998
70. Barrot L, Asfar P, Mauny F, LOCO2 Investigators and REVA Research Network: Liberal or conservative oxygen therapy for acute respiratory distress syndrome. N Engl J Med 2020; 382: 999-1008
71. Frat JP, Thille AW, Mercat A, FLORALI Study Group; REVA Network: High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015; 372: 2185-2196
72. Ni YN, Luo J, Yu H,. The effect of high-flow nasal cannula in reducing the mortality and the rate of endotracheal intubation when used before mechanical ventilation compared with conventional oxygen therapy and noninvasive positive pressure ventilation. A systematic review and meta-analysis. Am J Emerg Med 2018; 36: 226-233
73. Ou X, Hua Y, Liu J,. Effect of high-flow nasal cannula oxygen therapy in adults with acute hypoxemic respiratory failure: a meta-analysis of randomized controlled trials. CMAJ 2017; 189: E260-E267
74. Rochwerg B, Granton D, Wang DX,. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: A systematic review and meta-analysis. Intensive Care Med 2019; 45: 563-572
75. Raboud J, Shigayeva A, McGeer A,. Risk factors for SARS transmission from patients requiring intubation: A multicentre investigation in Toronto, Canada. PLoS One 2010; 5: e10717
76. Fowler RA, Guest CB, Lapinsky SE,. Transmission of severe acute respiratory syndrome during intubation and mechanical ventilation. Am J Respir Crit Care Med 2004; 169: 1198-1202
77. Leung CCH, Joynt GM, Gomersall CD,. Comparison of high-flow nasal cannula versus oxygen face mask for environmental bacterial contamination in critically ill pneumonia patients: A randomized controlled crossover trial. J Hosp Infect 2019; 101: 84-87
78. Cheung JC, Ho LT, Cheng JV,. Staff safety during emergency airway management for COVID-19 in Hong Kong. Lancet Respir Med 2020; 8: e19
79. Alraddadi BM, Qushmaq I, Al-Hameed FM, Saudi Critical Care Trials Group: Noninvasive ventilation in critically ill patients with the Middle East respiratory syndrome. Influenza Other Respir Viruses 2019; 13: 382-390
80. Arabi YM, Arifi AA, Balkhy HH,. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 2014; 160: 389-397
81. Zayed Y, Banifadel M, Barbarawi M,. Noninvasive oxygenation strategies in immunocompromised patients with acute hypoxemic respiratory failure: A pairwise and network meta-analysis of randomized controlled trials. J Intensive Care Med 2019 May 2. [online ahead of print]
82. Xu XP, Zhang XC, Hu SL,. noninvasive ventilation in acute hypoxemic nonhypercapnic respiratory failure: A systematic review and meta-analysis. Crit Care Med 2017; 45: e727-e733
83. Wang T, Zhang L, Luo K,. Noninvasive versus invasive mechanical ventilation for immunocompromised patients with acute respiratory failure: A systematic review and meta-analysis. BMC Pulm Med 201616: 129
84. Esquinas AM, Egbert Pravinkumar S,. Noninvasive mechanical ventilation in high-risk pulmonary infections: A clinical review. Eur Respir Rev 2014; 23: 427-438
85. Brochard L, Lefebvre JC, Cordioli RL,. Noninvasive ventilation for patients with hypoxemic acute respiratory failure. Semin Respir Crit Care Med 2014; 35: 492-500
86. Slutsky AS, Ranieri VM,. Ventilator-induced lung injury. N Engl J Med 2013; 369: 2126-2136
87. Hui DSC, Zumla A,. Severe acute respiratory syndrome: Historical, epidemiologic, and clinical features. Infect Dis Clin North Am 2019; 33: 869-889
88. Brochard L, Mancebo J, Wysocki M,. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333: 817-822
89. Rochwerg B, Brochard L, Elliott MW,. Suhail Raoof Members Of The Task Force: Official ERS/ATS clinical practice guidelines: Noninvasive ventilation for acute respiratory failure. Eur Respir J 2017; 50: 1602426
90. Patel BK, Wolfe KS, Pohlman AS,. Effect of noninvasive ventilation delivered by helmet vs face mask on the rate of endotracheal intubation in patients with acute respiratory distress syndrome: A randomized clinical trial. JAMA 2016; 315: 2435-2441
91. Hui DS, Chow BK, Lo T,. Exhaled air dispersion during noninvasive ventilation via helmets and a total facemask. Chest 2015; 147: 1336-1343
92. Walkey AJ, Goligher EC, Del Sorbo L,. low tidal volume versus non-volume-limited strategies for patients with acute respiratory distress syndrome. A systematic review and meta-analysis. Ann Am Thorac Soc 2017; 14: S271-S279
93. Amato MB, Barbas CS, Medeiros DM,. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998; 338: 347-354
94. Villar J, Kacmarek RM, Perez-Mendez L,. A high positive end-expiratory pressure, low tidal volume ventilatory strategy improves outcome in persistent acute respiratory distress syndrome: A randomized, controlled trial. Crit Care Med 2006; 34: 1311-1318
95. Brower RG, Matthay MA, Morris A, Acute Respiratory Distress Syndrome Network, Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342: 1301-1308
96. Brower RG, Shanholtz CB, Fessler HE,. Prospective, randomized, controlled clinical trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients. Crit Care Med 1999; 27: 1492-1498
97. Orme J Jr., Romney JS, Hopkins RO,. Pulmonary function and health-related quality of life in survivors of acute respiratory distress syndrome. Am J Respir Crit Care Med 2003; 167: 690-694
98. Wu G, Lu B,. [The application of low tidal volume pressure-controlled ventilation in patients with acute respiratory distress syndrome] [Chinese]. Hunan Yi Ke Da Xue Xue Bao 1998; 23: 57-58
99. Fan E, Del Sorbo L, Goligher EC, American Thoracic Society/European Society of Intensive Care Medicine; Society of Critical Care Medicine: An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2017; 195: 1253-1263
100. Rhodes A, Evans LE, Alhazzani W,. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med 2017; 45: 486-552
101. Thille AW, Rodriguez P, Cabello B,. Patient-ventilator asynchrony during assisted mechanical ventilation. Intensive Care Med 2006; 32: 1515-1522
102. Yasuda H, Nishimura T, Kamo T,. Optimal plateau pressure for patients with acute respiratory distress syndrome: A protocol for a systematic review and meta-analysis with meta-regression. BMJ Open 2017; 7: e015091
103. Brower RG, Lanken PN, MacIntyre N,. National Heart, Lung, and Blood Institute ARDS Clinical Trials Network: Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004; 351: 327-336
104. Meade MO, Cook DJ, Guyatt GH,. Lung Open Ventilation Study Investigators: Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: A randomized controlled trial. JAMA 2008; 299: 637-645
105. Mercat A, Richard JC, Vielle B,. Expiratory Pressure Study Group: Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: A randomized controlled trial. JAMA 2008; 299: 646-655
106. Briel M, Meade M, Mercat A,. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: Systematic review and meta-analysis. JAMA 2010; 303: 865-873
107. Guo L, Xie J, Huang Y,. Higher PEEP improves outcomes in ARDS patients with clinically objective positive oxygenation response to PEEP: A systematic review and meta-analysis. BMC Anesthesiol 2018; 18: 172
108. Walkey AJ, Del Sorbo L, Hodgson CL,. Higher PEEP versus lower peep strategies for patients with acute respiratory distress syndrome. A systematic review and meta-analysis. Ann Am Thorac Soc 2017; 14: S297-S303
109. Wiedemann HP, Wheeler AP, Bernard GR, National Heart Lung, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network, Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354: 2564-2575
110. Shi H, Han X, Jiang N,. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet Infect Dis 2020; 20: 425-434
111. Cornejo RA, Diaz JC, Tobar EA,. Effects of prone positioning on lung protection in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2013; 188: 440-448
112. Albert RK, Hubmayr RD,. The prone position eliminates compression of the lungs by the heart. Am J Respir Crit Care Med 2000; 161: 1660-1665
113. Nyren S, Radell P, Lindahl SG,. Lung ventilation and perfusion in prone and supine postures with reference to anesthetized and mechanically ventilated healthy volunteers. Anesthesiology 2010; 112: 682-687
114. Munshi L, Del Sorbo L, Adhikari NKJ,. Prone position for acute respiratory distress syndrome. A systematic review and meta-analysis. Ann Am Thorac Soc 2017; 14: S280-S288
115. Bloomfield R, Noble DW, Sudlow A,. Prone position for acute respiratory failure in adults. Cochrane Database Syst Rev 2015; (11): CD008095
116. Mora-Arteaga JA, Bernal-Ramirez OJ, Rodriguez SJ,. The effects of prone position ventilation in patients with acute respiratory distress syndrome. A systematic review and meta-analysis. Med Intensiva 2015; 39: 359-372
117. Lee JM, Bae W, Lee YJ,. The efficacy and safety of prone positional ventilation in acute respiratory distress syndrome: Updated study-level meta-analysis of 11 randomized controlled trials. Crit Care Med 2014; 42: 1252-1262
118. van der Voort PH, Zandstra DF,. () Enteral feeding in the critically ill: comparison between the supine and prone positions: A prospective crossover study in mechanically ventilated patients. Crit Care 2001; 5: 216-220
119. Reintam Blaser A, Starkopf J, Alhazzani W, ESICM Working Group on Gastrointestinal Function: Early enteral nutrition in critically ill patients: ESICM clinical practice guidelines. Intensive Care Med 2017; 43: 380-398
120. Murray MJ, DeBlock H, Erstad B,. Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Crit Care Med 2016; 44: 2079-2103
121. Griffiths M, Fan E, Baudouin SV,. New UK guidelines for the management of adult patients with ARDS. Thorax 2019; 74: 931-933
122. Claesson J, Freundlich M, Gunnarsson I,. Scandinavian clinical practice guideline on fluid and drug therapy in adults with acute respiratory distress syndrome. Acta Anaesthesiol Scand 2016; 60: 697-709
123. Papazian L, Aubron C, Brochard L,. Formal guidelines: Management of acute respiratory distress syndrome. Ann Intensive Care 2019; 9: 69
124. Alhazzani W, Alshahrani M, Jaeschke R,. Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. Crit Care 2013; 17: R43
125. Moss M, Huang DT, Brower RG, National Heart, Lung, and Blood Institute PETAL Clinical Trials Network: Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med 2019; 380: 1997-2008
126. Gebistorf F, Karam O, Wetterslev J,. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database Syst Rev 2016; (6): CD002787
127. Gattinoni L, Caironi P, Cressoni M,. Lung recruitment in patients with the acute respiratory distress syndrome. N Engl J Med 2006; 354: 1775-1786
128. Kacmarek RM, Villar J, Sulemanji D, Open Lung Approach Network: Open lung approach for the acute respiratory distress syndrome: A pilot, randomized controlled trial. Crit Care Med 2016; 44: 32-42
129. Xi XM, Jiang L, Zhu B, group RM,. Clinical efficacy and safety of recruitment maneuver in patients with acute respiratory distress syndrome using low tidal volume ventilation: A multicenter randomized controlled clinical trial. Chin Med J (Engl) 2010; 123: 3100-3105
130. Cavalcanti AB, Suzumura EA, Laranjeira LN, Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial Investigators, effect of lung recruitment and titrated positive end-expiratory pressure (peep) vs low peep on mortality in patients with acute respiratory distress syndrome: A randomized clinical trial. JAMA 2017; 318: 1335-1345
131. Hodgson CL, Tuxen DV, Davies AR,. A randomised controlled trial of an open lung strategy with staircase recruitment, titrated PEEP and targeted low airway pressures in patients with acute respiratory distress syndrome. Crit Care 2011; 15: R133
132. Hodgson CL, Cooper DJ, Arabi Y,. Maximal Recruitment Open Lung Ventilation in Acute Respiratory Distress Syndrome (PHARLAP). A phase ii, multicenter randomized controlled clinical trial. Am J Respir Crit Care Med 2019; 200: 1363-1372
133. Huh JW, Jung H, Choi HS,. Efficacy of positive end-expiratory pressure titration after the alveolar recruitment manoeuvre in patients with acute respiratory distress syndrome. Crit Care 2009; 13: R22
134. Goligher EC, Hodgson CL, Adhikari NKJ,. Lung recruitment maneuvers for adult patients with acute respiratory distress syndrome. A systematic review and meta-analysis. Ann Am Thorac Soc 2017; 14: S304-S311
135. Alshahrani MS, Sindi A, Alshamsi F,. Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus. Ann Intensive Care 2018; 8: 3
136. Combes A, Hajage D, Capellier G, EOLIA Trial Group, REVA, and ECMONet: Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med 2018; 378: 1965-1975
137. Goligher EC, Tomlinson G, Hajage D,. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a randomized clinical trial. JAMA 2018; 320: 2251-2259
138. Munshi L, Walkey A, Goligher E,. Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: A systematic review and meta-analysis. Lancet Respir Med 2019; 7: 163-172
139. MacLaren G, Fisher D, Brodie D,. Preparing for the most critically ill patients with COVID-19: The potential role of extracorporeal membrane oxygenation. JAMA 2020 Feb 19. [online ahead of print]
140. Fardet L, Galicier L, Lambotte O,. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 2014; 66: 2613-2620
141. Mehta P, McAuley DF, Brown M, HLH Across Speciality Collaboration, UK: COVID-19: Consider cytokine storm syndromes and immunosuppression. The Lancet 2020; 395: 1033-1034
142. Wang Y, Jiang W, He Q,. Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: Single-center experience from Wuhan, China. medRxiv 2020. 03.06.20032342
143. Siemieniuk RA, Meade MO, Alonso-Coello P,. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: A systematic review and meta-analysis. Ann Intern Med 2015; 163: 519-528
144. Lansbury L, Rodrigo C, Leonardi-Bee J,. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 2019; 2: CD010406
145. Lewis SR, Pritchard MW, Thomas CM,. Pharmacological agents for adults with acute respiratory distress syndrome. Cochrane Database Syst Rev 2019; 7: CD004477
146. Villar J, Ferrando C, Martinez D, dexamethasone in ARDS network: Dexamethasone treatment for the acute respiratory distress syndrome: A multicentre, randomised controlled trial. Lancet Respir Med 2020; 8: 267-276
147. Ranieri VM, Pettila V, Karvonen MK,. INTEREST Study Group: Effect of intravenous interferon beta-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome: A randomized clinical trial. JAMA 2020
148. Wu C, Chen X, Cai Y,. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020 Mar 13. [online ahead of print]
149. Rochwerg B, Oczkowski SJ, Siemieniuk RAC,. Corticosteroids in sepsis: An updated systematic review and meta-analysis. Crit Care Med 2018; 46: 1411-1420
150. Lian XJ, Huang DZ, Cao YS,. Reevaluating the role of corticosteroids in septic shock: An updated meta-analysis of randomized controlled trials. Biomed Res Int 2019; 2019: 3175047
151. Arabi YM, Mandourah Y, Al-Hameed F, Saudi Critical Care Trial Group: Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 2018; 197: 757-767
152. Hui DS,. Systemic corticosteroid therapy may delay viral clearance in patients with Middle East respiratory syndrome coronavirus infection. Am J Respir Crit Care Med 2018; 197: 700-701
153. Lee N, Allen Chan KC,. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol 2004; 31: 304-309
154. Uyeki TM, Bernstein HH, Bradley JS,. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa. Clin Infect Dis 2019; 68: 895-902
155. Arabi YM, Al-Omari A, Mandourah Y, Saudi Critical Care Trial Group: Critically ill patients with the Middle East respiratory syndrome: A multicenter retrospective cohort study. Crit Care Med 2017; 45: 1683-1695
156. Rice TW, Rubinson L, Uyeki TM, NHLBI ARDS Network: Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med 2012; 40: 1487-1498
157. Shieh WJ, Blau DM, Denison AM,. 2009 pandemic influenza A (H1N1): Pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol 2010; 177: 166-175
158. McCullers JA,. Do specific virus-bacteria pairings drive clinical outcomes of pneumonia? Clin Microbiol Infect 2013; 19: 113-118
159. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E,. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020; 101623
160. Schulman CI, Namias N, Doherty J,. The effect of antipyretic therapy upon outcomes in critically ill patients: A randomized, prospective study. Surg Infect (Larchmt) 2005; 6: 369-375
161. Young P, Saxena M, Bellomo R, HEAT Investigators, Australian and New Zealand Intensive Care Society Clinical Trials Group: Acetaminophen for fever in critically ill patients with suspected infection. N Engl J Med 2015; 373: 2215-2224
162. Haupt MT, Jastremski MS, Clemmer TP,. Effect of ibuprofen in patients with severe sepsis: A randomized, double-blind, multicenter study. The Ibuprofen Study Group. Crit Care Med 1991; 19: 1339-1347
163. Bernard GR, Wheeler AP, Russell JA,. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336: 912-918
164. Gozzoli V, Schottker P, Suter PM,. Is it worth treating fever in intensive care unit patients? Preliminary results from a randomized trial of the effect of external cooling. Arch Intern Med 2001; 161: 121-123
165. Memis D, Karamanlioglu B, Turan A,. Effects of lornoxicam on the physiology of severe sepsis. Crit Care 2004; 8: R474-R482
166. Honarmand H, Abdollahi M, Ahmadi A,. Randomized trial of the effect of intravenous paracetamol on inflammatory biomarkers and outcome in febrile critically ill adults. Daru 2012; 20: 12
167. Schortgen F, Clabault K, Katsahian S,. Fever control using external cooling in septic shock: A randomized controlled trial. Am J Respir Crit Care Med 2012; 185: 1088-1095
168. Niven DJ, Stelfox HT, Leger C,. Assessment of the safety and feasibility of administering antipyretic therapy in critically ill adults: a pilot randomized clinical trial. J Crit Care 2013; 28: 296-302
169. Yang YL, Liu DW, Wang XT,. Body temperature control in patients with refractory septic shock: Too much may be harmful. Chin Med J (Engl) 2013; 126: 1809-1813
170. Janz DR, Bastarache JA, Rice TW, Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis Study Group: Randomized, placebo-controlled trial of acetaminophen for the reduction of oxidative injury in severe sepsis: The Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis trial. Crit Care Med 2015; 43: 534-541
171. Schortgen F, Charles-Nelson A, Bouadma L,. Respective impact of lowering body temperature and heart rate on mortality in septic shock: Mediation analysis of a randomized trial. Intensive Care Med 2015; 41: 1800-1808
172. Wu J, Liu J, Zhao X,. Clinical characteristics of imported cases of COVID-19 in Jiangsu Province: A multicenter descriptive study. Clin Infect Dis 2020 Feb 29. [online ahead of print]
173. Stiehm ER,. Adverse effects of human immunoglobulin therapy. Transfus Med Rev 2013; 27: 171-178
174. Davey RT Jr., Fernández-Cruz E, Markowitz N,. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): A double-blind, randomised, placebo-controlled trial. Lancet Respir Med 2019; 7: 951-963
175. Beigel JH, Nam HH, Adams PL,. Antiviral research 2019; 167: Advances in respiratory virus therapeutics-A meeting report from the 6th Isirv Antiviral Group conference. 45-67
176. Arabi YM, Fowler R, Hayden FG,. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med 2020; 46: 315-328
177. Casadevall A, Pirofski L-A,. The convalescent sera option for containing COVID-19. J Clin Invest 2020; 130: 1545-1548
178. Hung IF, To KK, Lee CK,. Hyperimmune IV immunoglobulin treatment: A multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 2013; 144: 464-473
179. Stockman LJ, Bellamy R, Garner P,. SARS: Systematic review of treatment effects. PLoS Med 2006; 3: e343
180. Hung IF, To KK, Lee CK,. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52: 447-456
181. Luke TC, Kilbane EM, Jackson JL,. Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann Intern Med 2006; 145: 599-609
182. Kong LK, Zhou BP,. Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J 2006; 12: 489
183. Mair-Jenkins J, Saavedra-Campos M, Baillie K, Convalescent Plasma Study Group: The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral aetiology: A systematic review and exploratory metaanalysis. J Infect Dis 2014; 211: 80-90
184. XINHUANET.com: China puts 245 COVID-19 patients on convalescent plasma therapy. 2020. News release. Xinhua. Available at: http://www.xinhuanet.com/english/2020-02/28/c_138828177.htm. Accessed March 13, 2020
185. Arabi YM, Hajeer AH, Luke T,. Feasibility of Using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis 2016; 22: 1554-1561
186. van Griensven J, Edwards T, de Lamballerie X, Ebola-Tx Consortium: Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 2016; 374: 33-42
187. Beigel JH, Aga E, Elie-Turenne M-C,. Anti-influenza immune plasma for the treatment of patients with severe influenza A: A randomised, double-blind, phase 3 trial. Lancet Resp Med 2019; 7: 941-950
188. Huang X, Xu Y, Yang Q,. Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: A meta-analysis of randomized controlled trials. Sci Rep 2015; 5: 8528
189. Chu CM, Cheng VC, Hung IF, HKU/UCH SARS Study Group: Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax 2004; 59: 252-256
190. de Wilde AH, Jochmans D, Posthuma CC,. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 2014; 58: 4875-4884
191. Chan JF, Yao Y, Yeung ML,. Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J infect Dis 2015; 212: 1904-1913
192. Arabi YM, Asiri AY, Assiri AM, Saudi Critical Care Trials Group: Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-beta1b (MIRACLE trial): Statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials 2020; 21: 8
193. World Health Organization Informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection. Book Informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection, 2020
194. Cao B, Wang Y, Wen D,. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020 Mar 18. [online ahead of print]
195. World Health Organization: Informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection. 2020. Available at: https://apps.who.int/iris/bitstream/handle/10665/330680/WHO-HEO-RDBlueprint%28nCoV%29-2020.1-eng.pdf. Accessed March 10, 2020
196. Wang M, Cao R, Zhang L,. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269-271
197. Sheahan TP, Sims AC, Leist SR,. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERSCoV. Nat Commun 2020; 11: 222
198. de Wit E, Feldmann F, Cronin J,. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERSCoV infection. Proc Natl Acad Sci USA 2020; 117: 6771-6776
199. Mulangu S, Dodd LE, Davey RT Jr., PALM Consortium Study Team: A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019; 381: 2293-2303
200. Falzarano D, de Wit E, Martellaro C,. Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin. Sci Rep 2013; 3: 1686
201. Falzarano D, de Wit E, Rasmussen AL,. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013; 19: 1313-1317
202. Momattin H, Mohammed K, Zumla A,. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)-possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis 2013; 17: e792-8
203. Hart BJ, Dyall J, Postnikova E,. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 2014; 95: 571-577
204. Arabi YM, Shalhoub S, Mandourah Y,. Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: A multicenter observational study. Clin Infect Dis 2020; 70: 1837-1844
205. Chan JF, Chan KH, Kao RY,. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013; 67: 606-616
206. Arabi YM, Alothman A, Balkhy HH, And the MIRACLE trial group: Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): Study protocol for a randomized controlled trial. Trials 2018; 19: 81
207. Vincent MJ, Bergeron E, Benjannet S,. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; 2: 69
208. Wang M, Cao R, Zhang L,. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269-271
209. Yao X, Ye F, Zhang M,. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020 Mar 9. [online ahead of print]
210. Touret F, de Lamballerie X,. Of chloroquine and COVID-19. Antiviral Res 2020; 177: 104762
211. Roques P, Thiberville SD, Dupuis-Maguiraga L,. Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection. Viruses 2018; 10: 268
212. Gao J, Tian Z, Yang X,. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 4: 72-73
213. Multicenter Collaboration Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus Pneumonia: [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia] [Chinese]. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43: E019
214. Cortegiani A, Ingoglia G, Ippolito M,. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020 Mar 10. [online ahead of print]
215. Brunner HI, Ruperto N, Zuber Z, Paediatric Rheumatology International Trials Organisation PRINTO; Pediatric Rheumatology Collaborative Study Group (PRCSG): Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: Results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2015; 74: 1110-1117
216. Genovese MC, van Adelsberg J, Fan C, EXTEND study investigators: Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: Safety, efficacy and radiographic outcomes. Rheumatology (Oxford) 2018; 57: 1423-1431
217. Yokota S, Imagawa T, Mori M,. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 998-1006
218. Le RQ, Li L, Yuan W,. FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 2018; 23: 943
219. Chen X, Zhao B, Qu Y,. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. medRxiv 2020. 02.29.20029520
220. Campbell L, Chen C, Bhagat SS,. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: A systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 2011; 50: 552-562
221. Geng Z, Yu Y, Hu S,. Tocilizumab and the risk of respiratory adverse events in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomised controlled trials. Clin Exp Rheumatol 2019; 37: 318-323
222. Haffizulla J, Hartman A, Hoppers M, US Nitazoxanide Influenza Clinical Study Group: Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: A double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 2014; 14: 609-618
223. Gamino-Arroyo AE, Guerrero ML, McCarthy S, Mexico Emerging Infectious Diseases Clinical Research Network (LaRed): Efficacy and safety of nitazoxanide in addition to standard of care for the treatment of severe acute respiratory illness. Clin Infect Dis 2019; 69: 1903-1911